- Home
- OCS
as 07-26-2024 4:00pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
| Founded: | 2003 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 550.8M | IPO Year: | N/A |
| Target Price: | $30.17 | AVG Volume (30 days): | 10.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.05 - $14.50 | Next Earning Date: | 08-19-2024 |
| Revenue: | $995,455 | Revenue Growth: | -1.02% |
| Revenue Growth (this year): | 7.27% | Revenue Growth (next year): | 217.25% |
Latest Oculis Holding AG Ordinary shares News
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Oculis and EURETINA Announces the Ramin Tadayoni Award
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
The Wall Street Journal
2 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Business Wire
2 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Compare OCS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.